Eli Lilly & Co Stock Performance
as on October 24, 2026 at 2:15 pm IST
Day's Low
Day's High
$1,258.00$1,307.92
1.21%
Downside
2.71%
Upside
52 Week's Low
52 Week's High
$809.63$1,321.2136.42%
Downside
3.75%
Upside
Eli Lilly & Co share price movements today
- Previous Close
- $1,306.69
- Open
- $1,302.58
- Volume
- 1.5M
- Market Cap
- $1.2T
- Dividend Yield
- 0.53%
- Day's Low - High
- $1,258.00 - $1,307.92
- 52 Week Low - High
- $809.63 - $1,321.21
Eli Lilly & Co Historical Returns
- 1 Month Return
- + 7.75 %
- 3 Month Return
- + 6.47 %
- 1 Year Return
- + 54.27 %
- 3 Year Return
- + 114.96 %
- 5 Year Return
- + 422.45 %
Eli Lilly & Co Stock Fundamentals & Key Indicators
Check Eli Lilly & Co market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$1.2T
EPS (TTM)
29.89
Dividend Yield
0.53%
Quarterly Earnings Growth YOY
0.26%
PE Ratio (TTM)
43.72
Industry PE ratio
28.28
PEG Ratio
0.46
EBITDA
43.3B
Revenue (TTM)
79.7B
Profit Margin
83.40%
Return On Equity TTM
92.58%
Eli Lilly & Co vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Eli Lilly & Co with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % | Dividend Yield % |
|---|---|---|---|---|---|---|
| StrongBuy | $1.2T | 422.45% | 43.72 | 83.40% | 0.53% | |
| Buy | $621.2B | 61.13% | 40.57 | 68.81% | 2.05% | |
| Buy | $171.6B | -30.42% | 40.20 | 71.32% | 5.76% |
Stock Returns calculator for Eli Lilly & Co Stock including INR - Dollar returns
The Eli Lilly & Co stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.
Investment Value
₹1,00,000
Eli Lilly & Co investment value today
Current value as on today
₹1,66,752
Returns
₹66,752
(+66.75%)
Returns from Eli Lilly & Co Stock
₹54,275 (+54.27%)
Dollar Impact
₹12,477 (+12.48%)
Analyst Recommendation on Eli Lilly & Co Stock
Based on 20 analysts
90.00%
Buy
5.00%
Hold
5.00%
Sell
Based on 20 analysts, 90% of analysts recommend a 'BUY' rating for Eli Lilly & Co. Average target price of $1331.55
Eli Lilly & Co Share Price Target
Get share price movements and forecasts by analysts on Eli Lilly & Co.
What analysts predicted
4.36%UPSIDE
Target Price
$1331.55
Current Price
$1273.46
Analyzed by
20 Analysts
High
$1600
Target
$1331.55
Low
$940
Eli Lilly & Co target price $1331.55, a slight upside of 4.36% compared to current price of $1273.46. According to 20 analysts rating.
Indian Investors' Interest in Eli Lilly & Co Stock
Investment in Eli Lilly & Co Shares on INDmoney has dropped by -4.78% in the last 30 days, indicating reduced investment activity.
Time period: to
Search interest for Eli Lilly & Co Stock has increased by 15% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:15% versus previous 30 day period
Eli Lilly & Co Quarterly Profit & Loss
All numbers in Millions USD
Eli Lilly & Co Annual Profit & Loss
All numbers in Millions USD
Eli Lilly & Co Quarterly Cash Flow
All numbers in Millions USD
Eli Lilly & Co Annual Cash Flow
All numbers in Millions USD
Eli Lilly & Co News & Key Events
Today's Timeline - 24 October
Sat, 12:00 PM
-Eli Lilly presents Phase 1 data for Sofe-M, showing 79% response rate and 100% disease control in platinum-sensitive ovarian cancer.
Insights on Eli Lilly & Co
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Eli Lilly & Co. has shown strong revenue growth over the last six quarters, with revenue increasing from $12.72 billion to $22.97 billion. This represents an average quarterly growth rate of 11.0%.
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, LLY has outperformed top 5 stocks with highest market-cap in its industry
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, LLY has outperformed top 5 stocks with highest market-cap in its industry
- POSITIVE IMPACT
Price Rise
In the last 6 months, LLY stock has moved up by 44.1%
NEGATIVE IMPACTProfit Down
Eli Lilly & Co. has experienced a decline in net profit over the last two quarters. Specifically, their net profit fell from $7.39 billion to $7.09 billion, representing an average decrease of 4.1% per quarter.
About Eli Lilly & Co
Eli Lilly is a pharmaceutical company that discovers, develops, manufactures and markets medicines. Its therapeutic areas include diabetes, obesity, oncology, immunology and neuroscience.
Its portfolio includes products such as Mounjaro, Zepbound, Verzenio, Taltz, Ebglyss and Kisunla. Lilly combines scientific research and clinical development with manufacturing and healthcare distribution. Its commercial business depends on supplying approved medicines to customers through wholesalers, distributors and other relevant channels.
How Does Eli Lilly Make Money?
Eli Lilly makes money primarily by selling pharmaceutical products. Its recognised revenue reflects actual commercial sales after applicable rebates, discounts, returns and other deductions, alongside revenue from qualifying collaboration arrangements.
| Business area and customer need | What Eli Lilly provides | How Eli Lilly earns revenue |
|---|---|---|
| Diabetes and Obesity: Supply medicines for approved metabolic indications | Products including Mounjaro and Zepbound | Net sales of pharmaceutical products |
| Oncology: Supply cancer treatments | Products including Verzenio and other oncology medicines | Medicine sales through healthcare channels |
| Immunology: Supply treatments for approved immune-related conditions | Products including Taltz and Ebglyss | Net pharmaceutical sales |
| Neuroscience and other therapies: Supply medicines across additional treatment areas | Products including Kisunla and other medicines | Sales of approved products |
| Selected Collaborations: Commercialise medicines under partner arrangements | Shared development, licensing or commercial capabilities | Contracted collaboration revenue where applicable |
These therapeutic areas explain the portfolio rather than representing separate financial reporting segments.
How a prescription connects to company revenue
A medicine can pass through wholesalers, pharmacies and healthcare institutions before reaching the patient. Public systems, insurers and other intermediaries can influence access and reimbursement. Lilly earns from its own commercial supply and partner arrangements, not necessarily the full amount appearing on a patient's bill.
Why product price and net revenue differ
Published prices can be adjusted by rebates, discounts and other terms. Sales also depend on the amount of medicine actually supplied and the markets in which it is sold. The relevant commercial measure is the net revenue the company earns under those arrangements, rather than multiplying a headline price by an assumed number of patients.
Where repeat revenue comes from
Continuing prescribed treatment can create further product demand, while new patients and additional approved uses can broaden sales opportunities. Drug research creates potential future products but does not itself equal commercial revenue. Successful approvals, supply capacity, access and actual customer purchases connect the portfolio to earned sales.
| Organisation | Eli Lilly & Co |
| Headquarters | Lilly Corporate Center, Indianapolis, IN, 46285, US |
| Industry | Drug Manufacturers - General |
| CEO | David A. Ricks |
Key Management of Eli Lilly & Co
Name | Title |
|---|---|
Mr. David A. Ricks | Chairman, President & CEO |
Mr. Jacob S. Van Naarden | Executive VP, President of Lilly Oncology & Head of Corporate Business Development |
Mr. Donald A. Zakrowski | Senior VP of Finance & Chief Accounting Officer |
Mr. Diogo Rau | Executive VP and Chief Information & Digital Officer |
Mr. Eric Dozier | Executive VP & Chief People Officer |
Mr. Ilya Yuffa | Executive VP and President of Lilly USA & Global Customer Capabilities |
Mr. Lucas E. Montarce | Executive VP & CFO |
Dr. Daniel M. Skovronsky M.D., Ph.D. | Chief Scientific & Product Officer and President of Lilly Research Laboratories |
Ms. Anat Hakim J.D. | Executive VP, General Counsel & Secretary |
Mr. Michael Czapar | Senior Vice President of Investor Relations |
FAQs
What is Eli Lilly & Co share price today?
Eli Lilly & Co share price today is $1,273.46 as on at the close of the market. Eli Lilly & Co share today touched a day high of $1,307.92 and a low of $1,258.00.
What is the 52 week high and 52 week low for Eli Lilly & Co share?
Eli Lilly & Co share touched a 52 week high of $1,321.21 on and a 52 week low of $809.63 on . Eli Lilly & Co stock price today i.e. is closed at $1,273.46,which is 3.61% down from its 52 week high and 57.29% up from its 52 week low.
What is Eli Lilly & Co's market capitalisation today?
Eli Lilly & Co market capitalisation is $1.21T as on .
How to invest in Eli Lilly & Co Stock (LLY) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Eli Lilly & Co on INDmoney app. Click on Buy button.
What is the minimum amount required to buy Eli Lilly & Co Stock (LLY) from India?
Indian investors can start investing in Eli Lilly & Co (LLY) shares with as little as ₹94.94000244140625 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.40 in Eli Lilly & Co stock (as per the Rupee-Dollar exchange rate as on ).
Based on Eli Lilly & Co share’s latest price of $1,273.46 as on October 24, 2026 at 8:45 am IST, you will get 0.0079 shares of Eli Lilly & Co. Learn more about
fractional shares .
What are the returns that Eli Lilly & Co has given to Indian investors in the last 5 years?
Eli Lilly & Co stock has given 422.45% share price returns and 25.92% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?